| Description |
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research[1].
|
| Related Catalog |
|
| In Vivo |
Emicizumab (1.5-10 mg/kg，静脉注射，尾夹出血前 24 小时)部分纠正血友病a型出血模型中的失血，FVIII 等效为 9 U/dL[1]。 Emicizumab (3 mg /kg, 静脉注射) 联合低剂量 FVIII (10 U/dL) 时可提供额外的止血活性[1]。 Animal Model: FVIII-deficient mice[1] Dosage: 1.5-10 mg/kg Administration: IV, 24 hours before tail-clip bleeding was performed Result: Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.
|
| References |
[1]. Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748.
|
